Year-end Sale % OFF 
Abstract
Background Baicalin is a naturally occurring compound with anticancer, antioxidant, and anti-inflammatory properties. However, the mechanism underlying its anticancer activity on nonsmall cell lung cancer (NSCLC) remains unclear. Methods The effects of baicalin on the progression and metastasis of experimental NSCLC cell lines were studied in vitro and in vivo. Wound-healing and transwell assays were performed to evaluate the potency of baicalin and the motility and migration ability of NCI-H460 cells. Immunofluorescence assay, western blot assay, and immunohistochemistry test were conducted to investigate the inhibiting effect of baicalin on the epithelial-mesenchymal transition (EMT) of NSCLC. Results Baicalin inhibited the proliferation and migration of NCI-H446 human NSCLC cells in a dose-dependent manner, reduced the expression levels of phospho-3-phosphoinositide-dependent protein kinase 1 (p-PDK1) and phosphor-serine/threonine-protein kinase (p-AKT), reversed the levels of EMT markers, and inhibited the migration of NSCLC cells. Conclusions Baicalin impedes EMT by inhibiting the PDK1/AKT pathway in human NSCLC and thus may be an effective alternative treatment for carcinoma and a new candidate antimetastasis drug.
Highlights
Lung cancer is a common solid cancer with high cancerrelated mortality worldwide [1] accounting for 1.6 million deaths each year [2]
Our research showed that baicalin can suppress tumor progression by targeting the Phosphoinositide-dependent kinase-1 (PDK1)/AKT signaling pathway to inhibit epithelial-mesenchymal transition (EMT) on Nonsmall cell lung cancer (NSCLC)
Baicalin Inhibited NSCLC Proliferation. e molecular formula for baicalin is shown in Figure 1(a), and its effects on cell activity were determined by MTT assay
Summary
Lung cancer is a common solid cancer with high cancerrelated mortality worldwide [1] accounting for 1.6 million deaths each year [2]. Nonsmall cell lung cancer (NSCLC) is a histological subtype of lung cancer and accounts for 85% of its occurrence in the United States [4]. NSCLCs are of epithelial origin and include squamous cell carcinomas and adenocarcinomas. The mechanism underlying its anticancer activity on nonsmall cell lung cancer (NSCLC) remains unclear. E effects of baicalin on the progression and metastasis of experimental NSCLC cell lines were studied in vitro and in vivo. Immunofluorescence assay, western blot assay, and immunohistochemistry test were conducted to investigate the inhibiting effect of baicalin on the epithelial-mesenchymal transition (EMT) of NSCLC. Baicalin impedes EMT by inhibiting the PDK1/AKT pathway in human NSCLC and may be an effective alternative treatment for carcinoma and a new candidate antimetastasis drug
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
